Particularly among the elderly, Alzheimer's Disease (AD) is a common neurodegenerative disease impacting millions of people. The accumulation of beta-amyloid and tau proteins defines it; this causes the gradual decline of cognitive abilities. This work examines how peptides and the amino acid lysine might help modulate AD pathological processes. By focusing on experimental and observational studies on the effectiveness of these chemicals, the approach comprised a methodical review of papers published between 2010 and 2024. The findings show that specific peptides can destabilize amyloid plaques; lysine helps neuroprotection and lessens neuroinflammation. Though the results are encouraging, strong clinical trials must confirm human efficacy and safety. The conversation underlines the need to know the underlying molecular mechanisms and the need for new therapeutic interventions. Though peptides and lysine show great promise, ongoing studies are vital to create successful plans for treating AD to enhance patient quality of life.